fig7
![Ritonavir reverses resistance to docetaxel and cabazitaxel in prostate cancer cells with acquired resistance to docetaxel](https://image.oaes.cc/c45c672e-90ea-45df-8a5d-28b4693e0124/cdr60136.fig.7.jpg)
Figure 7. Effect of the cabazitaxel ritonavir combination in the docetaxel-resistant DU-145DOC10 cell line in the 3D clonogenic assay. (A) Concentration-effect curve showing a decrease in the cabazitaxel IC50 from 1.5 to 0.6 nM in the presence of 10 μM ritonavir; (B) Bliss Modeled T/C analysis shows synergistic effects at 10 μM ritonavir when combined with cabazitaxel concentrations of 1 and